Olympus, a global MedTech company committed to making people's lives healthier, safer and more fulfilling, announced the plan to establish a series of Digital Excellence Centers  following acquisition of London-based Odin Vision, a cloud-AI endoscopy company with a strong portfolio of commercially available computer-aided detection/diagnostic solutions and innovation pipeline of cloud-enabled applications. The acquisition has strengthened Olympus' recently announced str

BostonGene announced today the launch of its CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling and Spatial Proteomics solutions that provide a holistic view of a patient’s disease by integrating multiple AI-based molecular and immune profiling techniques that analyze tumor, microenvironment, and host immunity. The new offerings, in addition to the BostonGene Tumor PortraitTM test, will support and improve the efficacy of clinical trials and research and development effort

Valtruis, a WCAS company, announces the launch of TailorCare, a risk-based company that provides evidence-based, clinically-designed care navigation to patients living with joint, back, and muscle pain. TailorCare empowers patients to make informed treatment decisions based on their musculoskeletal (MSK) symptoms, goals, and lifestyle, which leads to better health outcomes, lower costs and happier patients. "MSK care is expensive, complex and riddled with patient frustration, c

CarepathRx Health System Solutions, a CarepathRx company and portfolio company of Nautic Partners, and Evernorth Health Services, a subsidiary of The Cigna Group announced a new strategic partnership and investment by Evernorth in CHSS. The strategic partnership brings together Evernorth’s diverse specialty and care expertise with CHSS’ robust pharmacy and infusion management capabilities, technology solutions, and health system relationships to improve, expand and accelerate phar

Avance Clinical, the leading award-winning Australian and North American CRO that offers ClinicReady and GlobalReady for early phase biotech companies to speed up the path to regulatory approval, says early phase oncology studies are increasingly more complex and demand more patients. Avance's ClinicReady and GlobalReady service platforms offer significant benefits to product development in oncology. According to Avance Clinical's Chief Scientific Officer Gabriel Kremmidioti

The Consumer Health Division of Bayer has launched a business unit focused on developing new Precision Health products across its range of everyday health categories. Bayer will prioritize developing products that enable people to take greater control of their own personal health through digital solutions that facilitate more informed choices based on personal insights and novel delivery mechanisms. The shift in the healthcare industry is clear, people need better self-care with the

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today that its PurISTSM test is now commercially available through Tempus for clinical use. PurIST is a novel RNA-expression test that identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) who are likely to experience longer overall survival (OS) with standard-of-care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC. Pan

Anatomy IT, the leading platform for healthcare IT and cybersecurity solutions, announced today the acquisition of IRIS Solutions, a respected and experienced leader in healthcare technology services for dental practices and healthcare providers. This strategic acquisition allows Anatomy IT to expand its presence in the ambulatory healthcare sector and bring its comprehensive suite of enterprise IT and Cybersecurity solutions, resources, and technology to a broader range of healthcare clients

Gene alterations in biliary tract cancer offer potential targets for current or future precision therapies. This is demonstrated by a highly acclaimed study conducted by Karl Landsteiner University of Health Sciences in collaboration with the Medical University of Vienna. In this study, cells from biliary tract cancer were examined for genetic alterations. The results demonstrate the potential of genetic profiling of tumors as a basis for promising and targeted therapies. Advanced c

Biological Dynamics, a life sciences company focused on developing and commercializing exosome isolation technology for earlier disease detection, today announced the publication of a case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy,” in Frontiers in Oncology, highlighting the successful detection of early-stage pancreatic ductal adenocarcinoma (PDAC) lesions using its exosome liquid biopsy assay, ExoVitaTM Pancreas.